ES2906571T3 - Composiciones de soluciones sólidas para AINEs - Google Patents

Composiciones de soluciones sólidas para AINEs Download PDF

Info

Publication number
ES2906571T3
ES2906571T3 ES16756963T ES16756963T ES2906571T3 ES 2906571 T3 ES2906571 T3 ES 2906571T3 ES 16756963 T ES16756963 T ES 16756963T ES 16756963 T ES16756963 T ES 16756963T ES 2906571 T3 ES2906571 T3 ES 2906571T3
Authority
ES
Spain
Prior art keywords
peg
weight
room temperature
liquid
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16756963T
Other languages
English (en)
Spanish (es)
Inventor
Robin Mark Bannister
John Brew
Richard Robert Reiley
Wilson Caparros-Wanderley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infirst Healthcare Ltd
Original Assignee
Infirst Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/821,687 external-priority patent/US9744132B2/en
Priority claimed from EP15180256.8A external-priority patent/EP3127556A1/en
Application filed by Infirst Healthcare Ltd filed Critical Infirst Healthcare Ltd
Application granted granted Critical
Publication of ES2906571T3 publication Critical patent/ES2906571T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES16756963T 2015-08-07 2016-08-08 Composiciones de soluciones sólidas para AINEs Active ES2906571T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/821,687 US9744132B2 (en) 2010-10-29 2015-08-07 Solid solution compositions and use in chronic inflammation
EP15180256.8A EP3127556A1 (en) 2015-08-07 2015-08-07 Solid solution compositions for nsaid
PCT/EP2016/068900 WO2017025517A1 (en) 2015-08-07 2016-08-08 SOLID SOLUTION COMPOSITIONS FOR NSAIDs

Publications (1)

Publication Number Publication Date
ES2906571T3 true ES2906571T3 (es) 2022-04-19

Family

ID=56800263

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16756963T Active ES2906571T3 (es) 2015-08-07 2016-08-08 Composiciones de soluciones sólidas para AINEs
ES21214529T Active ES3057447T3 (en) 2015-08-07 2016-08-08 Solid solution compositions for nsaids

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES21214529T Active ES3057447T3 (en) 2015-08-07 2016-08-08 Solid solution compositions for nsaids

Country Status (10)

Country Link
EP (2) EP3331568B1 (enExample)
JP (1) JP6989489B2 (enExample)
CN (1) CN108025078A (enExample)
AU (1) AU2016306610B2 (enExample)
CA (1) CA2994899C (enExample)
ES (2) ES2906571T3 (enExample)
IL (1) IL257385A (enExample)
MX (1) MX387217B (enExample)
PL (1) PL3331568T3 (enExample)
WO (1) WO2017025517A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
AU2022248850A1 (en) 2021-03-27 2023-11-09 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US9308213B2 (en) * 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
CN105007947B (zh) * 2013-01-14 2019-02-15 因佛斯特医疗有限公司 固溶体组合物及其在心血管疾病中的用途

Also Published As

Publication number Publication date
EP3988091A1 (en) 2022-04-27
ES3057447T3 (en) 2026-03-02
JP2018526351A (ja) 2018-09-13
EP3331568B1 (en) 2021-12-15
MX2018001584A (es) 2019-01-31
WO2017025517A1 (en) 2017-02-16
EP3331568A1 (en) 2018-06-13
CN108025078A (zh) 2018-05-11
CA2994899C (en) 2024-04-16
CA2994899A1 (en) 2017-02-16
PL3331568T3 (pl) 2022-02-28
EP3988091C0 (en) 2025-10-01
MX387217B (es) 2025-03-18
EP3988091B1 (en) 2025-10-01
IL257385A (en) 2018-04-30
JP6989489B2 (ja) 2022-01-05
AU2016306610A1 (en) 2018-03-01
AU2016306610B2 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
ES3057447T3 (en) Solid solution compositions for nsaids
ES2830033T3 (es) Composiciones de solución sólida y uso en enfermedad cardiovascular
CA2750219C (en) Transdermal delivery of diclofenac, carbamazepine and benzydamine
JP2012505909A (ja) 感覚成分を有する局所nsaid組成物
JP2010521442A (ja) 局所製剤処方
JP2011507826A (ja) トルペリゾンを含む医薬製剤
CN103079552A (zh) 包含氟比洛芬的外用药物组合物
US20140275265A1 (en) Therapeutic cream for application to skin
US20190083624A9 (en) Solid Solution Compositions and Use in Severe Pain
JP2025186498A (ja) 長時間作用型注射用製剤およびその使用
JP2018505905A (ja) 局所医薬製剤
JP7206199B2 (ja) 局所用抗炎症組成物
EP3127556A1 (en) Solid solution compositions for nsaid
ES2692663T3 (es) Método y composición farmacéutica mejorada para mejorar la entrega transdérmica del inhibidor PDE-5
PT2405892E (pt) Formulação farmacêutica compreendendo cetoprofeno e um éster polioxialquileno de um ácido gordo hidroxilado
TR2024002454A1 (tr) Topical compositions comprising nimesulide and diclofenac sodium and a salicylate
TW202610659A (zh) 用於治療例如發炎病症之組合物
ES2402289B1 (es) Composición farmacéutica para el tratamiento de la tendinitis y/o bursitis calcificada.
BR102017009057A2 (pt) composições farmacêuticas tópicas e uso das mesmas
BR112016012235B1 (pt) Composição veterinária injetável de dose única de ação prolongada e seu uso
PT1675621E (pt) Composições farmacêuticas de levendustina